{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:24:34Z","timestamp":1773948274863,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:00:00Z","timestamp":1535155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:00:00Z","timestamp":1535155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10637-018-0659-9","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T04:07:52Z","timestamp":1535170072000},"page":"375-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma"],"prefix":"10.1007","volume":"37","author":[{"given":"Charl\u00e9e","family":"Nardin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Borot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Astride","family":"Beaudoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Cattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Puzenat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Schillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,25]]},"reference":[{"issue":"8","key":"659_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473\u2013486","journal-title":"Nat Rev Clin Oncol"},{"key":"659_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225","journal-title":"Eur J Cancer"},{"issue":"6\u20137","key":"659_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","volume":"140","author":"M Lecouflet","year":"2013","unstructured":"Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D et al (2013) Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 140(6\u20137):448\u2013451","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"659_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/01676830.2014.949792","volume":"33","author":"E McElnea","year":"2014","unstructured":"McElnea E, N\u00ed Mh\u00e9al\u00f3id A, Moran S, Kelly R, Fulcher T (2014) Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit Amst Neth 33(6):424\u2013427","journal-title":"Orbit Amst Neth"},{"issue":"4","key":"659_CR5","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","volume":"27","author":"G Borodic","year":"2011","unstructured":"Borodic G, Hinkle DM, Cia Y (2011) Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 27(4):e87\u2013e88","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"2","key":"659_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164(2):303\u2013307","journal-title":"Eur J Endocrinol"},{"key":"659_CR7","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1097\/IOP.0000000000000509","volume":"33","author":"CA Sheldon","year":"2017","unstructured":"Sheldon CA, Kharlip J, Tamhankar MA (2017) Inflammatory Orbitopathy associated with Ipilimumab. Ophthal Plast Reconstr Surg 33:S155\u2013S158","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"659_CR8","first-page":"171","volume":"91","author":"F Nasr","year":"2018","unstructured":"Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J et al (2018) Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer Oxf Engl 1990 91:171\u2013173","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"659_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000485742","volume":"7","author":"P Campredon","year":"2018","unstructured":"Campredon P, Imbert P, Mouly C, Grunenwald S, Mazi\u00e8res J, Caron P (2018) Severe inflammatory Ophthalmopathy in a Euthyroid patient during Nivolumab treatment. Eur Thyroid J 7(2):84\u201387","journal-title":"Eur Thyroid J"},{"key":"659_CR10","first-page":"1","volume":"30","author":"R Alnabulsi","year":"2018","unstructured":"Alnabulsi R, Hussain A, DeAngelis D (2018) Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Orbit Amst Neth 30:1\u20134","journal-title":"Orbit Amst Neth"},{"issue":"1","key":"659_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF03345116","volume":"26","author":"L Bartalena","year":"2003","unstructured":"Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A (2003) Orbital radiotherapy for Graves\u2019 ophthalmopathy: useful or useless? Safe or dangerous? J Endocrinol Investig 26(1):5\u201316","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"659_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0161-6420(97)30301-7","volume":"104","author":"I Mombaerts","year":"1997","unstructured":"Mombaerts I, Koornneef L (1997 Mar) Current status in the treatment of orbital myositis. Ophthalmology 104(3):402\u2013408","journal-title":"Ophthalmology"},{"issue":"6939","key":"659_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(6939):506\u2013511","journal-title":"Nature"},{"issue":"1","key":"659_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1677\/jme.0.0310021","volume":"31","author":"DA Chistiakov","year":"2003","unstructured":"Chistiakov DA, Turakulov RI (2003) CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 31(1):21\u201336","journal-title":"J Mol Endocrinol"},{"issue":"8","key":"659_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.humimm.2006.05.003","volume":"67","author":"S Han","year":"2006","unstructured":"Han S, Zhang S, Zhang W, Li R, Li Y, Wang Z, Xie Y, Mao Y (2006) CTLA4 polymorphisms and ophthalmopathy in Graves\u2019 disease patients: association study and meta-analysis. Hum Immunol 67(8):618\u2013626","journal-title":"Hum Immunol"},{"issue":"7","key":"659_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol Off J Am Soc Clin Oncol 35(7):785\u2013792","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0659-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:30:23Z","timestamp":1678559423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0659-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,25]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0659-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,25]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not have any disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}